newsfilter
← Latest News
Business Wire·

Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Pivotal Phase 3 NEAT clinical trial evaluating lead asset, eDSP, for the treatment of A-T remains on track with topline results expected in first quarter of 2026 Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage